NCT07882303Not yet recruiting
Native T1 Mapping and ECV in Chronic Hemolytic Anemia
The Added Value of Native T1 Mapping and Extracellular Volume Calculation in the Detection of Myocardial Iron Overload and Fibrosis in Patients With Chronic Hemolytic Anemias
Source: ClinicalTrials.gov · Last updated 20 Oct 2026
Brief summary (registry, in English)
This cross-sectional study aims to evaluate the diagnostic performance of native T1 mapping and extracellular volume fraction for the detection of myocardial iron overload and fibrosis in patients with chronic hemolytic anemia compared with T2\* relaxometry.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 54 (estimated)
- First submitted
- 13 Oct 2026
- Start date
- 20 Oct 2026
- Primary completion date
- 20 Oct 2027
- Lead sponsor
- Assiut University
- Diseases
- Thalassaemia
- NCT number
- NCT07882303
What you commit to
- Study type: Observational
- Planned participants: 54
- From 20 Oct 2026 to the primary completion date, 20 Oct 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Unrelated cardiovascular disease or prior cardiac surgery
Other illness
- Non-diagnostic cardiac magnetic resonance
- Non-transfusional cause of cardiac iron overload
Other
- \- MRI contraindication
- Gadolinium contraindication (native sequences still performed)
- Refusal of informed consent
Who the study is looking for
- \- Confirmed transfusion-dependent chronic hemolytic anemia
- Age 7 years or older
- Able to cooperate with cardiac magnetic resonance without anesthesia
- Written informed consent
Age in the registry: 7 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.